Vaccine preparations, pharmaceutical preparations, attenuated influenza virus, vaccination methods, methods for the prevention of an infectious disease, methods of treatment or prevention of cancers, vaccine compositions and pharmaceutical compositions
Номер патента: PL398576A1
Опубликовано: 08-10-2012
Автор(ы): Adolf Garcia-Sastre, Peter Palese, Thomas Muster
Принадлежит: Mount Sinai School of Medicine
Опубликовано: 08-10-2012
Автор(ы): Adolf Garcia-Sastre, Peter Palese, Thomas Muster
Принадлежит: Mount Sinai School of Medicine
Реферат: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.
Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
Номер патента: EP4396197A1. Автор: David Klatzmann,Hugo Lujan. Владелец: Universidad Catolica de Cordoba UCC. Дата публикации: 2024-07-10.